Literature DB >> 8298607

Involvement of brain CCK in the adaptation of gut motility to digestive status and stress: a review.

L Buéno1.   

Abstract

Cholecystokinin is involved at both central and peripheral level in the control of gut motility. At CNS level, CCK8 appears to play a major role in the adaptation of duodeno-jejunal motility to the postprandial state, ie the disruption of the migrating motor complex. CCK8 microinjected into the ventro-medial nucleus of the hypothalamus (VLH) induces a fed-like pattern not reproduced by similar administration into the hypothalamus. Furthermore, CCKA antagonists such as devazepide injected into the VMH just prior to the meal shortens the duration of the postprandial pattern of activity, an effect not reproduced by similar injection into the LH. Similarly the colonic motor activation observed after feeding is suppressed by devazepide injected into the VMH in rats. In addition, icv administration of CCKA but not CCKB receptor antagonist prevents meal- and CCK8-induced colonic hyperkinesia in dogs. In rats, emotional stress is associated with an increase in colonic motility related to the central release of CRF. We have shown that CCK8 injected centrally, at a lower dose than that producing an increase in colonic motility, is able to prevent stress-induced colonic motor alteration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8298607     DOI: 10.1016/0928-4257(93)90036-s

Source DB:  PubMed          Journal:  J Physiol Paris        ISSN: 0928-4257


  2 in total

1.  Effect of cholecystokinin octapeptide and atropine on human colonic motility, tone, and transit.

Authors:  M D O'Brien; M Camilleri; G M Thomforde; J A Wiste; R B Hanson; A R Zinsmeister
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.199

2.  The multicomponent medication Spascupreel attenuates stress-induced gut dysfunction in rats.

Authors:  Vassilia Theodorou; Catherine Beaufrand; Sophie Yvon; Guylaine Laforge; Yvonne Burmeister; Andrea Müller; Bernd Seilheimer; Lionel Bueno; Helene Eutamene
Journal:  Neurogastroenterol Motil       Date:  2020-02-14       Impact factor: 3.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.